Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sildenafil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A known ✓ | O76074 | 20/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.82 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.82 |
| ▸ | PDE2A | O00408 | 1/20 | 0.82 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.82 |
| ▸ | PDE6D | O43924 | 1/20 | 0.82 |
| ▸ | PDE8A | O60658 | 1/20 | 0.82 |
| ▸ | PDE9A | O76083 | 1/20 | 0.82 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.82 |
| ▸ | HTR1A | P08908 | 1/20 | 0.82 |
| ▸ | PDE6A | P16499 | 1/20 | 0.82 |
| ▸ | PDE6G | P18545 | 1/20 | 0.82 |
| ▸ | PDE4A | P27815 | 1/20 | 0.82 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.82 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.82 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.82 |
| ▸ | PDE6B | P35913 | 1/20 | 0.82 |
| ▸ | PDE6C | P51160 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sildenafil SCHEMBL33982 | 1.00 | PDE5A (1.00) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL6509338 | 1.00 | PDE5A (1.00) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL29424508 | 1.00 | PDE5A (1.00) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL405881 | 1.00 | PDE5A (1.00) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL28791531 | 0.99 | PDE5A (0.99) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL27980438 | 0.99 | PDE5A (0.99) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL6685385 | 0.99 | PDE5A (0.99) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL19410963 | 0.99 | PDE5A (0.99) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL17101160 | 0.99 | PDE5A (0.97) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL7374712 | 0.98 | PDE5A (0.96) | PDE5AABCC4PDE3BPDE3APDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200046813-A1 | Novel Method of Treating Macular Degeneration Using Botulinum Toxin-Based Pharmaceuticals | BORODIC GARY E (US) | 2020-02-13 | — | — | US | disclosed |
| US-20190008870-A1 | COMPOSITIONS AND METHODS FOR LIPID METABOLISM DISORDER | JANSFAT BIOTECHNOLOGY CO LTD (TW) | 2019-01-10 | — | — | US | disclosed |
| US-20180042927-A1 | PHOSPHODIESTERASE INHIBITORS TO REPAIR BRAIN AND/OR RETINAL INJURY IN HUMAN NEWBORNS | WINTERMARK PIA (CA) | 2018-02-15 | — | — | US | disclosed |
| EP-3244930-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | Neonc Technologies Inc. (US) | 2017-11-22 | — | — | EP | disclosed |
| CN-107334770-A | Compositions and methods for treating disorders of lipid metabolism | 健脂生物科技股份有限公司 | 2017-11-10 | — | — | CN | disclosed |
| EP-3241552-A1 | COMPOSITIONS AND METHODS FOR LIPID METABOLISM DISORDER | Jansfat Biotechnology Co., Ltd. (TW) | 2017-11-08 | — | — | EP | disclosed |
| US-20170312286-A1 | COMPOSITIONS AND METHODS FOR LIPID METABOLISM DISORDER | JANSFAT BIOTECHNOLOGY CO., LTD. (TW) | 2017-11-02 | — | — | US | disclosed |
| WO-2016115147-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | NEONC TECHNOLOGIES INC. (US) | 2016-07-21 | — | — | WO | disclosed |
| WO-2015134695-A1 | METHOD OF MITIGATING THE SIDE EFFECTS OF A PHOSPHODIESTERASE TYPE V INHIBITOR IN A SUBJECT | VYRIX PHARMACEUTICALS, INC. (US) | 2015-09-11 | — | — | WO | disclosed |
| EP-2693876-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | Sphaera Pharma Pte. Ltd (SG) | 2014-02-12 | — | — | EP | disclosed |
| EP-1204766-A4 | SAMPLE ARRAYS AND HIGH-THROUGHPUT TESTING THEREOF TO DETECT INTERACTIONS | TRANSFORM PHARMACEUTICALS INC (US) | 2003-09-17 | — | — | EP | disclosed |
| EP-1301619-A1 | SYSTEM AND METHOD FOR OPTIMIZING TISSUE BARRIER TRANSFER OF COMPOUNDS | Transform Pharmaceuticals, Inc. (US) | 2003-04-16 | — | — | EP | disclosed |
| EP-1248869-A2 | HIGH-THROUGHPUT FORMATION, IDENTIFICATION, AND ANALYSIS OF DIVERSE SOLID-FORMS | Transform Pharmaceuticals, Inc. (US) | 2002-10-16 | — | — | EP | disclosed |
| EP-1204766-A1 | SAMPLE ARRAYS AND HIGH-THROUGHPUT TESTING THEREOF TO DETECT INTERACTIONS | Transform Pharmaceuticals, Inc. (US) | 2002-05-15 | — | — | EP | disclosed |
| EP-1187614-A1 | SUBSTITUTED PIPERIDINES AS MELANOCORTIN-4 RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2002-03-20 | — | — | EP | disclosed |
| WO-2001051919-A9 | HIGH-THROUGHPUT FORMATION, IDENTIFICATION, AND ANALYSIS OF DIVERSE SOLID-FORMS | TRANSFORM PHARMACEUTICALS INC (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002006518-A1 | SYSTEM AND METHOD FOR OPTIMIZING TISSUE BARRIER TRANSFER OF COMPOUNDS | TRANSFORM PHARMACEUTICALS, INC. (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-2001051919-A2 | HIGH-THROUGHPUT FORMATION, IDENTIFICATION, AND ANALYSIS OF DIVERSE SOLID-FORMS | TRANSFORM PHARMACEUTICALS, INC. (US) | 2001-07-19 | — | — | WO | disclosed |
| WO-2001009391-A1 | SAMPLE ARRAYS AND HIGH-THROUGHPUT TESTING THEREOF TO DETECT INTERACTIONS | TRANSFORM PHARMACEUTICALS, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2000074679-A1 | SUBSTITUTED PIPERIDINES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170312286-A1 | COMPOSITIONS AND METHODS FOR LIPID METABOLISM DISORDER | GYS2, PYGL, GYS1 | PDE5A 14/4885ABCC4 2209/4885PDE3B 78/4885 |
| US-20190008870-A1 | COMPOSITIONS AND METHODS FOR LIPID METABOLISM DISORDER | GYS2, PYGL, GYS1 | PDE5A 14/4885ABCC4 2209/4885PDE3B 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.